Florian Barvencik

Florian Barvencik

Auto-generated profile, based on publicly available information

Florian Barvencik

Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Injury
Verified
Journal Article
Closed access
MSMaciej JK Simon
Maciej JK Simon
FBFlorian Barvencik
Florian Barvencik
MLMoritz Luttke
Moritz Luttke
MAMichael Amling
Michael Amling
HMHans-Wilhelm Mueller-Wohlfahrt
Hans-Wilhelm Mueller-Wohlfahrt
PUPeter Ueblacker
Peter Ueblacker

29 October 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JSJulian Stürznickel
Julian Stürznickel
TRTim Rolvien
Tim Rolvien
ADAlena Delsmann
Alena Delsmann
SBSebastian Butscheidt
Sebastian Butscheidt
FBFlorian Barvencik
Florian Barvencik
RORalf Oheim
Ralf Oheim
Reduced bone mineral density (BMD, i.e., Z‐score ≤‐2.0) occurring at a young age (i.e., premenopausal women, men <50 years) in the absence of secondary osteoporosis is considered early‐onset osteoporosis (EOOP). Mutations affecting the WNT signaling pathway are of special interest due to their key role in bone mass regulation. Here, we analyzed the effects of relevant LRP5 and LRP6 variants on the clinical phenotype, bone turnover, BMD and bone microarchitecture. After exclusion of secondary osteoporosis, EOOP patients (n=372) were genotyped by gene panel sequencing, and segregation analysis of variants in LRP5/LRP6 was performed. The clinical assessment comprised the evaluation of bone turnover parameters, BMD by dual‐energy X‐ray absorptiometry, and microarchitecture via high‐resolution peripheral quantitative computed tomography (HR‐pQCT). In 50 individuals (31 EOOP index patients, 19 family members), relevant variants affecting LRP5 or LRP6 were detected (42 LRP5 and 8 LRP6 variants), including 10 novel variants. Seventeen variants were classified as disease causing, 14 were variants of unknown significance, and 19 were BMD‐associated SNPs. One patient harbored compound heterozygous LRP5 mutations causing osteoporosis‐pseudoglioma syndrome. Fractures were reported in 37/50 individuals, comprising vertebral (18/50) and peripheral (29/50) fractures. Low bone formation was revealed in all individuals. A Z‐score ≤‐2.0 was detected in 31/50 individuals, and values at the spine were significantly lower than those at the hip (‐2.1 ± 1.3 vs. ‐1.6 ± 0.8; p=0.003). HR‐pQCT analysis (n=34) showed impaired microarchitecture in trabecular and cortical compartments. Significant differences regarding the clinical phenotype were detectable between index patients and family members but not between different variant classes. Relevant variants in LRP5 and LRP6 contribute to EOOP in a substantial number of individuals, leading to a high number of fractures, low bone formation, reduced Z‐scores, and impaired microarchitecture. This detailed skeletal characterization improves the interpretation of known and novel LRP5 and LRP6 variants.

1 April 2017 in Injury
Verified
Journal Article
Closed access
TRTim Rolvien
Tim Rolvien
TSTobias Schmidt
Tobias Schmidt
SBSebastian Butscheidt
Sebastian Butscheidt
MAMichael Amling
Michael Amling
FBFlorian Barvencik
Florian Barvencik

28 October 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
TSTobias Schmidt
Tobias Schmidt
CSConstantin Schmidt
Constantin Schmidt
MAMichael Amling
Michael Amling
JKJan Kramer
Jan Kramer
FBFlorian Barvencik
Florian Barvencik
Background: Tissue-nonspecific alkaline phosphatase (TNSALP) encoded by the ALPL gene is of particular importance for bone mineralization. Mutation in the ALPL gene can lead to persistent low ALP activity resulting in the rare disease Hypophosphatasia (HPP) that is characterized by disturbed bone and dental mineralization. While severe forms are extremely rare with an estimated prevalence of 1/100.000, recent studies suggest that moderate form caused by heterozygous mutations are much more frequent with an estimated prevalence of 1/508. The purpose of this study was to estimate the prevalence of low AP levels in the population based on laboratory measurements. Methods: In this study, the prevalence of low AP activity and elevated pyridoxal-5-phosphate (PLP) levels was analyzed in 6.918.126 measurements from 2011 to 2016 at a single laboratory in northern Germany. Only laboratory values of subjects older than 18 years of age were included. Only the first measurement was included, all repeated values were excluded. Results: In total, 8.46% of the measurements of a total of 6.918.126 values showed a value < 30 U/L. 0.59% of the subjects with an ALP activity below 30 U/L had an additional PLP measurement. Here, 6.09% showed elevated pyridoxal-5-phosphate (PLP) levels. This suggest that 0.52% (1:194) of subjects show laboratory signs of HPP. Conclusion: These data support the genetic estimation that the prevalence of moderate forms of HPP may be significantly higher than expected. Based on these data, we recommend automatically measurement of PLP in the case of low ALP activity and a notification to the ordering physician that HPP should be included in the differential diagnosis and further exploration is recommended.

21 November 2013 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
JBJonathan Brown
Jonathan Brown
ASArne Sandmann
Arne Sandmann
AIAnita Ignatius
Anita Ignatius
MAMichael Amling
Michael Amling
FBFlorian Barvencik
Florian Barvencik
In Germany, vitamin D intake from food and synthesis in the skin is low, which leads to low 25(OH)D serum concentrations. In contrast to many other countries, general vitamin D food fortification is still prohibited in Germany, although the European Commission published a regulatory framework to harmonize addition of vitamins to foods. Thus the purpose of our study was to develop a vitamin D fortification model, taking into account all vitamin D sources with the goal to fulfill requirements of intake recommendations or preferable 25(OH)D serum concentrations. Finally, the aim was to assess the suitability of different carriers and associated risks.

15 November 2020 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
NJNico Maximilian Jandl
Nico Maximilian Jandl
TSTobias Schmidt
Tobias Schmidt
TRTim Rolvien
Tim Rolvien
JSJulian Stürznickel
Julian Stürznickel
KCKonstantin Chrysostomou
Konstantin Chrysostomou
FBFlorian Barvencik
Florian Barvencik
Hypophosphatasia (HPP) is a rare inborn error of metabolism due to a decreased activity of tissue nonspecific alkaline phosphatase (TNSALP). As the onset and severity of HPP are heterogenous, it can be challenging to determine the pathogenicity of detected rare ALPL variants in symptomatic patients. We aimed to characterize patients with rare ALPL variants to propose which patients can be diagnosed with adult HPP. We included 72 patients with (1) clinical symptoms of adult HPP or positive family history and (2) low TNSALP activity and/or high pyridoxal 5′-phosphate (PLP) levels, who underwent ALPL gene sequencing. The patients were analyzed and divided into three groups depending on ALPL variant pathogenicity according to the classification of the American College of Medical Genetics and Genomics (ACMG). Reported pathogenic (n = 34 patients), rare (n = 17) and common (n = 21) ALPL variants only were found. Muscular complaints were the most frequent symptoms (> 80%), followed by bone affection (> 50%). Tooth involvement was significantly more common in patients with pathogenic or rare ALPL variants. Seven rare variants could be classified as likely pathogenic (ACMG class 4) of which five have not yet been described. Inconclusive genetic findings and less specific symptoms make diagnosis difficult in cases where adult HPP is not obvious. As not every pathogenic or rare ALPL variant leads to a manifestation of HPP, only patients with bone complications and at least one additional complication concerning teeth, muscle, central nervous and mental system, repeated low TNSALP activity and high PLP levels should be diagnosed as adult HPP if rare ALPL gene variants of ACMG class 4 or higher support the diagnosis.